BRCA2 and cancer: Overall, the estimated age-specific relative and absolute risks suggest that, in addition to breast and ovarian cancers, the clinical management of BRCA1/2 carriers should focus on cancer sites, which now show robust associations, such as prostate (BRCA2 carriers only), pancreatic, and possibly stomach cancers.